

Code	Phone	E-Mail	Date
2018-001155-13	06102 7480-0	regulatory@gbg.de	23 March 2020

A Phase III, Randomized, Open-Label Study Investigating the Addition of Durvalumab to an Anthracycline-Taxane based Chemotherapy in Early-Stage Triple-Negative Breast Cancer

EudraCT-Nr.: 2018-001155-13
Protocol-Code: GBG 99-GeparTreize
Sponsor: GBG Forschungs GmbH
Medicinal Product: MEDI4736 (Durvalumab)

Sponsor Statement – Trial results

Dear Madams and Sirs,

the above-mentioned trial was discontinued globally during the preparation of the trial.
No sites were initiated, no patient entered the study, therefore no results / data are available.